sclerostin (SOST)
Jump to navigation
Jump to search
Function
- bone homeostasis (putative)
- osteocyte-derived inhibitor of osteoblast activity[3]
Structure
- belongs to the sclerostin family
- contains 1 CTCK domain (C-terminal cystine knot-like domain)
Compartment
Alternative splicing
named isoforms=2
Expression
- widely expressed at low levels
- highest expression in bone, cartilage, kidney, liver, bone marrow, & primary osteoblasts differentiated for 21 days (osteocytes)
Pathology
- defects in SOST are assosiated with sclerosteosis
Pharmacology
- romosozumab a monoclonal antibody that binds to sclerostin & increases bone formation may be useful for treatment of osteoporosis[3]
Physiology
- osteocytes make sclerostin[4]
- sclerostin generally inhibits bone formation
- when osteocytes sense bone-loading activities, sclerostin secretion diminishes, allowing for increased bone formation[4]
More general terms
References
- ↑ UniProt http://www.uniprot.org/uniprot/Q9BQB4.html
- ↑ GeneReviews https://www.genecards.org/cgi-bin/carddisp.pl?gene=SOST
- ↑ 3.0 3.1 3.2 McClung MR et al Romosozumab in Postmenopausal Women with Low Bone Mineral Density. N Engl J Med. Jan 1, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24382002 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1305224
Becker CB Sclerostin Inhibition for Osteoporosis - A New Approach. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24382003 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1315500 - ↑ 4.0 4.1 4.2 Misra M Which Exercise Is Best for Bone Health? Medscape. Nov 14, 2022 https://www.medscape.com/viewarticle/983792